These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

846 related items for PubMed ID: 29102254

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
    Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.
    J Clin Oncol; 2017 Jul 10; 35(20):2299-2305. PubMed ID: 28410011
    [Abstract] [Full Text] [Related]

  • 4. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
    Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA.
    Eur Urol; 2017 Jun 10; 71(6):952-960. PubMed ID: 28081860
    [Abstract] [Full Text] [Related]

  • 5. Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Zhou YX, Hu QC, Zhu YJ, Mu XL, Liu JY, Chen Y.
    Eur J Med Res; 2023 Oct 11; 28(1):422. PubMed ID: 37822001
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
    Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, Zietman AL.
    Eur Urol; 2012 Apr 11; 61(4):705-11. PubMed ID: 22101114
    [Abstract] [Full Text] [Related]

  • 12. Pathologic and survival outcomes following radical cystectomy for "progressive" and "de novo" muscle-invasive bladder cancer: A meta-analysis stratified by neoadjuvant chemotherapy status.
    Xia L, Dadabhoy A, Wood EL, Mehta SV, Roberson DS, Guzzo TJ, Bivalacqua TJ, Daneshmand S.
    Urol Oncol; 2024 Oct 11; 42(10):333.e1-333.e13. PubMed ID: 38697874
    [Abstract] [Full Text] [Related]

  • 13. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients.
    Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG.
    Eur Urol; 2012 May 11; 61(5):1039-47. PubMed ID: 22381169
    [Abstract] [Full Text] [Related]

  • 14. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer.
    Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA.
    Int J Radiat Oncol Biol Phys; 2016 Dec 01; 96(5):1028-1036. PubMed ID: 27727064
    [Abstract] [Full Text] [Related]

  • 15. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis.
    Bhindi B, Frank I, Mason RJ, Tarrell RF, Thapa P, Cheville JC, Costello BA, Pagliaro LC, Karnes RJ, Thompson RH, Tollefson MK, Boorjian SA.
    Eur Urol; 2017 Nov 01; 72(5):660-664. PubMed ID: 28545841
    [Abstract] [Full Text] [Related]

  • 16. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Tang Y, Lin L, Xiao Y, Meng L, Yang Y, Li X.
    Clin Transl Oncol; 2024 Feb 01; 26(2):446-455. PubMed ID: 37389736
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA.
    Hanna N, Trinh QD, Seisen T, Vetterlein MW, Sammon J, Preston MA, Lipsitz SR, Bellmunt J, Menon M, Choueiri TK, Abdollah F.
    Eur Urol Oncol; 2018 May 01; 1(1):83-90. PubMed ID: 31100232
    [Abstract] [Full Text] [Related]

  • 18. Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    Su X, Dong C, Liao W, Liu W.
    World J Surg Oncol; 2023 Aug 29; 21(1):271. PubMed ID: 37641150
    [Abstract] [Full Text] [Related]

  • 19. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
    Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W.
    Eur Urol; 2014 Jul 29; 66(1):120-37. PubMed ID: 24613684
    [Abstract] [Full Text] [Related]

  • 20. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP, Korets R, Chang P, Wagner A, Olumi AF, Gershman B.
    Urol Oncol; 2022 Jun 29; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.